We are live on
!
Find out more
CCA
Cravens & Co Advisors Portfolio holdings
AUM
$154M
1-Year Est. Return
17.67%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+17.67%
3 Year Est. Return
+52.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$5.29M
(+4.1%)
Cap. Flow
-$4.95M
Cap. Flow
% of AUM
-3.7%
Top 10 Holdings %
Top 10 Hldgs %
67.11%
Holding
59
New
2
Increased
29
Reduced
20
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.19M |
| 2 |
Starbucks
SBUX
|
+$782K |
| 3 |
DFSV
Dimensional US Small Cap Value ETF
DFSV
|
+$427K |
| 4 |
Illumina
ILMN
|
+$298K |
| 5 |
Dimensional US Core Equity 2 ETF
DFAC
|
+$279K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SmartFinancial
SMBK
|
+$4.94M |
| 2 |
AbbVie
ABBV
|
+$1.02M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$816K |
| 4 |
Rio Tinto
RIO
|
+$723K |
| 5 |
Cenovus Energy
CVE
|
+$276K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 11.03% |
| 2 | Technology | 6.7% |
| 3 | Communication Services | 4.56% |
| 4 | Consumer Discretionary | 3.99% |
| 5 | Healthcare | 3.66% |
Similar funds
CPCP
SOWAS
AFC
SHU
FW
FGI
HPM
MDP
Cravens & Co Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Cravens & Co Advisors held 59 positions worth $134M, up 4.1% from $129M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Cravens & Co Advisors withdrew a net $4.95M in Q2 2025, closing 4 positions and reducing 20 holdings. Its most notable exit was AbbVie, an estimated $1.02M position sold in full.
By sector, the portfolio is most concentrated in Financials at 11% of assets, down from 14% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Cravens & Co Advisors opened a new position in Eli Lilly worth $1.2M.
- Cravens & Co Advisors's largest Q2 2025 buy was Eli Lilly: 1,534 shares worth $1.2M.
- Cravens & Co Advisors added most to Starbucks in Q2 2025, an estimated $782K increase.
- Cravens & Co Advisors's biggest Q2 2025 reduction was SmartFinancial, cutting an estimated $4.94M.
- Cravens & Co Advisors fully exited AbbVie in Q2 2025, selling an estimated $1.02M.
- Cravens & Co Advisors's ten largest holdings make up 67% of its $134M portfolio in Q2 2025.
- Cravens & Co Advisors opened 2 new positions and closed 4 in Q2 2025.
- Cravens & Co Advisors's portfolio value rose 4.1% quarter-over-quarter to $134M.
Based on Cravens & Co Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.